-

Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform patients’ lives, announced that Dirk Thye, M.D., the company’s Chief Executive Officer, will present at the Sidoti Virtual Investor Conference on Thursday, August 17, 2023, at 3:15 p.m. Eastern Time (12:15 p.m. Pacific Time).

A live webcast of the investor presentation will be accessible on the Events page under the News & Events heading of Quince’s Investor Relations website at ir.quincetx.com. An archive of the webcast will be available shortly following the end of the live event.

About Quince Therapeutics

Quince Therapeutics is a biotechnology company focused on acquiring, developing, and commercializing innovative therapeutics that transform the lives of patients suffering from debilitating and rare diseases. For more information, visit www.quincetx.com and follow Quince Therapeutics on LinkedIn and @Quince_Tx on Twitter.

Contacts

Quince Therapeutics Contact:
Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com

Industry:

Quince Therapeutics, Inc.

NASDAQ:QNCX
Release Versions
English
$Cashtags
$QNCX

Contacts

Quince Therapeutics Contact:
Stacy Roughan
Quince Therapeutics, Inc.
Vice President, Corporate Communications & Investor Relations
ir@quincetx.com

Social Media Profiles
Quince on LinkedIn
Quince on Twitter
More News From Quince Therapeutics, Inc.

Quince Therapeutics Announces Last Patient Last Visit in Phase 3 NEAT Clinical Trial in Patients with Ataxia-Telangiectasia

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the last patient has completed their last visit in the company’s pivotal Phase 3 NEAT (Neurological Effects of eDSP in Subjects with A-T; NCT06193200/IEDAT-04-2022) clinical trial of its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), in patie...

Quince Therapeutics Announces Publication of Use of eDSP in Early-Stage Clinical Studies in Pulmonary and Inflammatory Bowel Disorders

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, announced the publication of a summary of early-stage clinical studies of its Phase 3 lead asset, eDSP (dexamethasone sodium phosphate [DSP] encapsulated in a patient’s own red blood cells), in pulmonary and inflammatory bowel disorders (IBD) in the scientific journal Frontiers i...

Quince Therapeutics to Participate at Investor Events in December 2025

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that senior management will participate at three investor events in December 2025: Dirk Thye, M.D., Quince’s Chief Executive Officer and Chief Medical Officer, will participate at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025,...
Back to Newsroom